A new real-world research study evaluates the safety profile and discontinuation rates of Cosentyx (secukinumab) in patients with axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA)
| CONTEXT: This report published in “Frontiers in Medicine” provides new context on when and why patients stop taking this specific biologic treatment. The retrospective observational study of patients with axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) provided a wealth of data most notable of which may be the finding that obesity and other components of metabolic syndrome were predictors of longer survival on the therapy, therefore suggesting Cosentyx as a good choice for obese patients. READ TIME: 2 mins 1. “They therefore performed a multicenter retrospective observational study of patients with AxSpa or PsA who were prescribed and received at least 1 dose of SEC.” 2. “About two-thirds of patients who are prescribed secukinumab (Cosentyx) for axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) remained on the drug after a year, according to a new report based on real-world evidence.” 3. ““However, we currently have no consistent data on long-term survival of SEC in patients with AxSpA and PsA in routine clinical practice,” the investigators wrote.” 4. “The investigators said the finding that obesity was linked with better drug survival was interesting, since previous reports have suggested patients who are obese and who have psoriasis tend to have a poor therapeutic response to SEC.” 5. ““Therefore, SEC could be a good therapeutic choice in obese patients with AxSpA and PsA as opposed to [tumor necrosis factor inhibitor] agents.”” Source URL: https://www.ajmc.com/view/secukinumab-retention-high-in-real-world-study-of-patients-with-psa-axspa |